Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

LYZZ Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 16
Average round size
info
The average size of a deal this fund participated in
$48M
Portfolio companies 14
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

The venture was found in Asia in China. The leading representative office of defined VC is situated in the Shanghai.

The overall number of key employees were 3.

The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018. The average startup value when the investment from LYZZ Capital is 100-500 millions dollars.

The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures China, Vertex Ventures, Tahoe Venture. In the next rounds fund is usually obtained by HBM Healthcare Investments AG.

For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Qpex Biopharma, Alpha Biopharma, Neurelis. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Medical, Biopharma. The fund has no exact preference in some founders of portfolio startups.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of LYZZ Capital:
Typical Co-investors
LYZZ Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after LYZZ Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alua Capital New York, New York, United States
American Financial Group Cincinnati, Ohio, United States
Atland Ventures Minneapolis, Minnesota, United States
Bear Creek Capital Florida, Oviedo, United States
BGF Industries Greensboro, North Carolina, United States
BLUEHALO Beijing, Beijing, China
Fondation d'Aide aux Entreprises Geneva, Geneve, Switzerland
HAWKSBERG INVESTMENTS LTD -
India Accelerator Gurgaon, Haryana, India
Jiuyouque Touzi China, Hangzhou, Zhejiang
Longworth Venture Partners Massachusetts, United States, Waltham
MarathonArtists LABs England, London, United Kingdom
Plus Capital California, Marina Del Rey, United States
Rose Capital Connecticut, Greenwich, United States
Taylor Ventures California, Salinas, United States
The Leona M. and Harry B. Helmsley Charitable Trust Sioux Falls, South Dakota, United States
The Singh Family Trusts -
University of California Investment Office -
VGI Global Media Bangkok, Krung Thep, Thailand
Wuhan Port Industry Enterprise Management China, Hubei, Wuhan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Mojia Bioscience

Biotechnology
$80M22 Jun 2022 Guang'an City, Sichuan, China

SUSTAO

29 Apr 2022 -

OncoMyx Therapeutics

Biotechnology
Health Diagnostics
Medical
Therapeutics
$50M09 Dec 2021 Phoenix, Arizona, United States

OncoMyx Therapeutics

Biotechnology
Health Care
Therapeutics
$50M08 Dec 2021 Tempe, Arizona, United States

Wugen

Biotechnology
Therapeutics
$172M15 Jul 2021 St Louis, Missouri, United States

Neurelis

Biotechnology
Health Care
Medical
Pharmaceutical
$114M10 Mar 2021 California, United States

Jumpcode Genomics

Biotechnology
Health Care
Wellness
$21M20 Jan 2021 Carlsbad, California, United States

Biopharma
Biotechnology
Pharmaceutical
$7M10 Jul 2020 San Diego, California, United States

Mabworks

Biopharma
Biotechnology
Clinical Trials
$160M16 Apr 2020 Dongcheng District, Beijing, China
News
Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.

Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway

– Onchilles Pharma announced a $7m Series A financing from LYZZ Capital and includes a $500k investment from the University of Chicago’s Startup Investment Fund.
– The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation.
– Research published in today’s issue of Cell is the first to describe this pathway where human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing non-cancer cells.
– ELANE is an entirely new treatment paradigm with the potential to have broad and selective cancer killing activity regardless of genetic mutation or anatomical origin.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LYZZ Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: